These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 39069671)

  • 1. Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy.
    Núñez K; Sandow T; Gimenez J; Hibino M; Cohen A; Thevenot P
    Cancer Res Commun; 2024 Aug; 4(8):2163-2173. PubMed ID: 39069671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization - Implications in treatment outcomes.
    Núñez KG; Sandow T; Gimenez J; Hibino M; Fort D; Cohen AJ; Thevenot PT
    Eur J Cancer; 2024 Jan; 196():113442. PubMed ID: 37988841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.
    Zang C; Zhao Y; Qin L; Liu G; Sun J; Li K; Zhao Y; Sheng S; Zhang H; He N; Zhao P; Wang Q; Li X; Peng Y; Dong T; Zhang Y
    BMC Cancer; 2021 Sep; 21(1):1007. PubMed ID: 34496797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
    Salem R; Gordon AC; Mouli S; Hickey R; Kallini J; Gabr A; Mulcahy MF; Baker T; Abecassis M; Miller FH; Yaghmai V; Sato K; Desai K; Thornburg B; Benson AB; Rademaker A; Ganger D; Kulik L; Lewandowski RJ
    Gastroenterology; 2016 Dec; 151(6):1155-1163.e2. PubMed ID: 27575820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
    Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
    J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
    Cheng Y; Gunasegaran B; Singh HD; Dutertre CA; Loh CY; Lim JQ; Crawford JC; Lee HK; Zhang X; Lee B; Becht E; Lim WJ; Yeong J; Chan CY; Chung A; Goh BKP; Chow PKH; Chan JKY; Ginhoux F; Tai D; Chen J; Lim SG; Zhai W; Choo SP; Newell EW
    Immunity; 2021 Aug; 54(8):1825-1840.e7. PubMed ID: 34270940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients.
    Saxena A; Meteling B; Kapoor J; Golani S; Danta M; Morris DL; Bester L
    Int J Surg; 2014 Dec; 12(12):1403-8. PubMed ID: 25091398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection.
    Chang YM; Wieland A; Li ZR; Im SJ; McGuire DJ; Kissick HT; Antia R; Ahmed R
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32759317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
    Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
    J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex.
    Kim SH; Lee BR; Kim SM; Kim S; Kim MS; Kim J; Lee I; Kim HS; Nam GH; Kim IS; Song K; Choi Y; Lee DS; Park WY
    Exp Mol Med; 2024 Jun; 56(6):1461-1471. PubMed ID: 38866910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
    Hilgard P; Hamami M; Fouly AE; Scherag A; Müller S; Ertle J; Heusner T; Cicinnati VR; Paul A; Bockisch A; Gerken G; Antoch G
    Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
    Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
    J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.
    Otano I; Escors D; Schurich A; Singh H; Robertson F; Davidson BR; Fusai G; Vargas FA; Tan ZMD; Aw JYJ; Hansi N; Kennedy PTF; Xue SA; Stauss HJ; Bertoletti A; Pavesi A; Maini MK
    Mol Ther; 2018 Nov; 26(11):2553-2566. PubMed ID: 30217730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
    Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
    Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report.
    Liu C; Shao J; Dong Y; Xu Q; Zou Z; Chen F; Yan J; Liu J; Li S; Liu B; Shen J
    Front Immunol; 2021; 12():685126. PubMed ID: 34326839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.
    Butterfield LH; Ribas A; Potter DM; Economou JS
    Cancer Immunol Immunother; 2007 Dec; 56(12):1931-43. PubMed ID: 17522860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.